Exelixis Inc

Healthcare · Biotechnology

58.40$ +0.8% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Income Statement

Exelixis Inc (EXEL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 629 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement EXEL
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	62	78	81	99	153	120	212	186	225	229	215	240	272	240	227	259	231	270	270	385	328	451	356	419	412	424	409	470	472	480	425	637	540	567	555	568	598	599	611	629	2,436
Cost of Revenue	2.5	1.9	3.2	3.0	4.7	4.2	5.6	6.0	7.4	7.4	7.5	7.5	7.5	11	9.3	9.2	8.7	9.0	13	15	12	13	13	13	15	16	14	18	19	22	21	18	17	20	19	19	19	26	20	21	86
Gross Profit	60	76	78	96	148	116	207	180	218	221	208	233	264	230	218	250	222	261	257	370	317	438	343	406	396	408	394	452	453	458	404	620	522	547	536	549	579	572	591	608	2,350
Research & Development	20	24	23	28	29	32	38	42	45	57	63	82	97	94	102	115	177	154	159	149	163	222	157	199	199	337	234	233	333	245	228	211	223	249	212	200	199	213	200	212	824
Selling, General & Administrative	32	13	34	41	38	46	53	52	48	52	60	51	51	40	–	60	88	57	98	102	99	68	123	115	115	119	131	142	138	91	114	132	112	91	137	135	124	71	140	148	482
Total Operating Expenses	53	37	57	69	67	78	90	94	93	110	123	141	149	152	165	175	265	237	262	247	265	322	260	322	314	456	366	374	471	376	375	344	386	384	349	335	343	337	340	360	1,379
Operating Income	7.3	39	20	27	81	37	116	86	125	112	85	92	116	77	53	76	-43	24	-4.6	123	52	117	87	84	83	-48	22	78	-18	82	29	276	136	163	187	214	237	235	251	248	972
Interest Expense	7.8	4.5	4.4	4.3	8.7	17	–	–	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	1.8	4.8	9.5	11	26	–	–	26	–	–	–	–	–	–	–	–	–	–	–
Pre-Tax Income	-11	35	17	18	85	39	118	88	129	116	91	100	123	85	60	81	-38	28	-2.0	125	53	118	85	89	92	-31	48	100	5.8	103	49	293	155	185	206	230	252	253	268	263	1,035
Income Tax Expense	7.8	4.2	0.1	0.6	3.2	0.4	2.5	0.9	2.3	-244	15	21	25	16	11	14	-6.0	-0.3	-3.6	29	15	23	17	18	19	-1.3	8.3	19	4.8	18	12	67	37	45	46	46	59	8.2	57	51	175
Net Income	-11	35	17	18	81	38	116	87	127	360	76	79	97	69	49	67	-32	28	1.6	96	38	95	69	71	73	-30	40	81	1.0	86	37	226	118	140	160	185	194	245	210	212	861
EBITDA	-3.2	39	21	27	85	38	118	89	131	116	87	95	118	94	55	78	-40	27	-1.4	129	58	120	83	88	88	-48	29	106	12	110	69	284	195	171	213	238	260	243	275	263	1,040

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings